InMed Pharmaceuticals has now announced top-line results from both the 755-101-HV and 755-102-HV Phase I trials. Trial 755-101-HV was conducted in 22 healthy adult volunteers with intact skin, while 755-102-HV was conducted in eight healthy volunteers with small wounds. Both trials indicated that INM-755 was safe and well tolerated. There were no systemic or serious adverse effects, nor were there any adverse event-related withdrawals. Additionally, systemic drug concentrations were very low, wh ....
11 Jan 2021
InMed Pharmaceuticals - INM-755 Phase I complete, on to Phase II
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
InMed Pharmaceuticals - INM-755 Phase I complete, on to Phase II
InMed Pharmaceuticals Inc. (MWG0:FRA) | 0 0 0.0%
- Published:
11 Jan 2021 -
Author:
Maxim Jacobs -
Pages:
6
InMed Pharmaceuticals has now announced top-line results from both the 755-101-HV and 755-102-HV Phase I trials. Trial 755-101-HV was conducted in 22 healthy adult volunteers with intact skin, while 755-102-HV was conducted in eight healthy volunteers with small wounds. Both trials indicated that INM-755 was safe and well tolerated. There were no systemic or serious adverse effects, nor were there any adverse event-related withdrawals. Additionally, systemic drug concentrations were very low, wh ....